Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2010

View Archived Issues

Cornerstone and Alitair collaborate on drug development for respiratory diseases

Ajinomoto claims new inhibitors of IL-12/IL-23 production

ArQule discloses new FGFR inhibitors

Taisho discovers new DP2 receptor antagonists

Japanese researchers describe new KIF11 inhibitors

IGFBP-7 mediates oncogene-induced senescence in papillary thyroid carcinoma

DAB2IP gene SNP correlates with susceptibility to abdominal aortic aneurism

Regadenoson SPECT is safe and tolerated in patients with CKD and ESRD

TBR-652 exhibits potent anti-HIV activity in phase II trial

Nanobin encapsulation improves therapeutic efficacy of As2O3 in solid tumors

Lexicon reacquires rights to several serotonin synthesis inhibitors from Symphony Icon

Merck & Co. identifies new gamma-secretase modulators

Mallinckrodt claims novel diagnostic agents for renal disorders

FDA clears first-in-human trial of N-6022

Seattle Genetics and Genentech expand antibody-drug conjugate agreement

Diamyd receives upfront payment from OMJP under Diamyd collaboration

Oxygen signs CRADA with U.S. navy to study decompression sickness therapy

FusoGen presents phase IIb data on sifuvirtide in HIV

Pharmachem Laboratories offers to acquire all assets from Forbes Medi-Tech

First patient receives treatment in phase Ib expansion trial of CUDC-101

Patient enrollment advances ahead of schedule in phase III Probuphine trial

Northwest reports phase I/II data on DCVax-Brain personalized immune therapy

MiddleBrook Pharmaceuticals completes sale of assets to Victory Pharma

Mitsubishi Tanabe transfers Kerlong marketing rights to sanofi-aventis

Taisho Pharma discontinues development of TS-022 for atopic dermatitis with pruritus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...